---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-158211"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-07-11T23:59:59+00:00"
generated_at: "2026-05-18T06:59:34.892239+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma amends CSO Kastelein's employment agreement with enhanced severance

## Summary
- Amended agreement effective July 1, 2025; replaces November 2022 pact.
- Termination without cause entitles Kastelein to 12 months base salary, earned bonus, and prorated annual bonus.
- Change-in-control trigger: same severance plus acceleration of all time-based stock options and equity awards.
- Exercise period for certain vested options extended upon qualifying termination.
- Kastelein remains Chief Scientific Officer and a director; no departure announced.

## SEC filing metadata
- accession: 0001193125-25-158211
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312525158211/0001193125-25-158211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312525158211/d915297d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-158211
- JSON: https://secwatch.observer/filing/0001193125-25-158211.json
- Plain text: https://secwatch.observer/filing/0001193125-25-158211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.